Company
ALK-Abello A-S
Headquarters: Horsholm, Denmark
Employees: 2,537
CEO: Mr. Carsten Hellmann
Market Cap
kr.20.14 Billion
DKK as of Jan. 1, 2023
US$2.89 Billion
ALK-Abello A-S Categories
Denmark
languages
Healthcare
languages
Biotechnology
Denmark Healthcare
Denmark Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
|
Novo Nordisk
|
$304.61 B |
CSL Limited
|
$93.24 B |
Regeneron Pharmaceuticals, Inc.
|
$79.53 B |
| Marinomed Biotech AG | $76.72 B |
|
Vertex Pharmaceuticals Incorporated
|
$74.13 B |
Sector: Healthcare
| Company | Market Cap (USD) |
|---|---|
|
UnitedHealth Group
|
$495.37 B |
|
Johnson & Johnson
|
$461.85 B |
|
Lilly
|
$347.61 B |
|
Novo Nordisk
|
$304.61 B |
|
Pfizer
|
$287.63 B |
Detailed Description
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company offers GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.
Stocks & Indices
ALK-Abello A-S has the following listings and related stock indices.
Stock: OMXC: ALK.B
Stock: FSX: 4AJ